18F-FDG PET/CT-directed biopsy: does it offer incremental benefit?

Area of Science:

• Nuclear Medicine
• Radiology
• Oncology

Background:

• Image-guided biopsies are crucial for definitive histopathological diagnosis.
• Positron emission tomography/computed tomography (PET/CT) provides metabolic information that may aid in biopsy targeting.

Purpose of the Study:

• To evaluate the added value of pre-biopsy PET/CT metabolic information in image-guided biopsies.
• To determine if PET/CT enhances diagnostic yield compared to standard CT-guided biopsies.

Main Methods:

• Retrospective analysis of 112 patients who underwent image-guided biopsies with available pre-procedural PET/CT scans.
• Biopsies were targeted to hypermetabolic regions identified on PET/CT, confirmed by coregistration with intraprocedural CT.
• Diagnostic success was defined by achieving a definitive histopathological diagnosis.

Main Results:

• An incremental benefit from PET/CT information was observed in 47.3% of all biopsies.
• Higher diagnostic yields were noted in biopsies of bone (66.6%) and soft tissue (57.8%) lesions.
• The most frequent incremental benefit (30 cases) occurred when targeting the focal hypermetabolic area within a larger lesion.

Conclusions:

• Coregistration of PET/CT metabolic data with intraprocedural CT images effectively guides needle placement into viable lesional tissue.
• This integrated imaging approach significantly increases the probability of obtaining a definitive diagnosis through image-guided biopsies.